Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MYNZ Another Market Opportunity For Mainz Biomed
https://investorbrandmedia.com/mynz-stock-alert/
$MYNZ Another Market Opportunity For Mainz Biomed
https://investorbrandmedia.com/mynz-stock-alert/
Definitely picking up now
Mainz BioMed (NASDAQ: $MYNZ) Could just have the answer to save countless lives WORLDWIDE
https://investorbrandmedia.com/mynz-stock-alert/
Mainz BioMed (NASDAQ: $MYNZ) Could just have the answer to save countless lives WORLDWIDE
https://investorbrandmedia.com/mynz-stock-alert/
Mainz BioMed (NASDAQ: $MYNZ) Could just have the answer to save countless lives WORLDWIDE
https://investorbrandmedia.com/mynz-stock-alert/
There’s No Doubt About It, Early Detection Saves Lives Mainz Biomed N.V. (NASDAQ: $MYNZ)
https://investorbrandmedia.com/mynz-stock-alert/
There’s No Doubt About It, Early Detection Saves Lives Mainz Biomed N.V. (NASDAQ: $MYNZ)
https://investorbrandmedia.com/mynz-stock-alert/
There’s No Doubt About It, Early Detection Saves Lives Mainz Biomed N.V. (NASDAQ: $MYNZ)
https://investorbrandmedia.com/mynz-stock-alert/
Nice pre market volume
That’s what I like to see!!
$MYNZ Great Opportunity - Trading Closer To Its 52-week Low With The Overall Market ROUT
https://investorbrandmedia.com/mynz-stock-alert/#
$MYNZ Great Opportunity - Trading Closer To Its 52-week Low With The Overall Market ROUT
https://investorbrandmedia.com/mynz-stock-alert/#
We are going through a time in history that will be remembered for years to come. These markets are ruthless right now. The strong will be rewarded
$MYNZ The Global Pancreatic Cancer Therapeutics Market Size is predicted to be worth USD 6,575 Million by 2030, with a CAGR of 7.2% from 2022 to 2030.
https://investorbrandmedia.com/mynz-stock-alert/
$MYNZ The Global Pancreatic Cancer Therapeutics Market Size is predicted to be worth USD 6,575 Million by 2030, with a CAGR of 7.2% from 2022 to 2030.
https://investorbrandmedia.com/mynz-stock-alert/
Bid keeps upticking
$MYNZ Another Market Opportunity For Mainz Biomed ?
https://investorbrandmedia.com/mynz-stock-alert/
$MYNZ Another Market Opportunity For Mainz Biomed ?
https://investorbrandmedia.com/mynz-stock-alert/
Mainz BioMed (NASDAQ: $MYNZ) Could just have the answer to save countless lives WORLDWIDE
https://investorbrandmedia.com/mynz-stock-alert/
Mainz BioMed (NASDAQ: $MYNZ) Could just have the answer to save countless lives WORLDWIDE
https://investorbrandmedia.com/mynz-stock-alert/
Let’s keep it going!
Biotech Stocks could be recession proof as bond market plunges ( $MYNZ, $RVNC, $AXSM, $ABBV)
https://www.marketwatch.com/press-release/biotech-stocks-could-be-recession-proof-as-bond-market-plunges-mynz-rvnc-axsm-abbv-2022-09-26?reflink=mw_share_twitter
Biotech Stocks could be recession proof as bond market plunges ( $MYNZ, $RVNC, $AXSM, $ABBV)
https://www.marketwatch.com/press-release/biotech-stocks-could-be-recession-proof-as-bond-market-plunges-mynz-rvnc-axsm-abbv-2022-09-26?reflink=mw_share_twitter
$MYZN Thus, positioned better than at any time in history to accelerate growth, with cash and products supporting its mission, $MYNZ is an investment consideration based on merit, not hype.
https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26?reflink=mw_share_twitter
$MYZN Thus, positioned better than at any time in history to accelerate growth, with cash and products supporting its mission, $MYNZ is an investment consideration based on merit, not hype.
https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26?reflink=mw_share_twitter
$MYZN Thus, positioned better than at any time in history to accelerate growth, with cash and products supporting its mission, $MYNZ is an investment consideration based on merit, not hype.
https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26?reflink=mw_share_twitter
Holding green
Agreed bro!
Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer Screening Diagnostics $MYNZ
https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26?reflink=mw_share_twitter
Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer Screening Diagnostics $MYNZ
https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26?reflink=mw_share_twitter
Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer Screening Diagnostics $MYNZ
https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26?reflink=mw_share_twitter
There’s No Doubt About It, Early Detection Saves Lives Mainz Biomed N.V. (NASDAQ: $MYNZ)
https://investorbrandmedia.com/mynz-stock-alert/
There’s No Doubt About It, Early Detection Saves Lives Mainz Biomed N.V. (NASDAQ: $MYNZ)
https://investorbrandmedia.com/mynz-stock-alert/
Nice and green today in pre market
Here's What Mainz Biomed B.V.'s (NASDAQ: $MYNZ) Shareholder Ownership Structure Looks Like https://finance.yahoo.com/news/heres-mainz-biomed-b-v-114435919.html
Here's What Mainz Biomed B.V.'s (NASDAQ: $MYNZ) Shareholder Ownership Structure Looks Like https://finance.yahoo.com/news/heres-mainz-biomed-b-v-114435919.html
$MYNZ
Key Corporate & Product Development Highlights
Accelerated international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC)
Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial Officer
Established partnership with Dante Labs to market ColoAlert in Italy and the United Arab Emirates
Initiated and enrolled the first patient in an international clinical study (ColoFuture) evaluating the integration of novel mRNA biomarkers into ColoAlert – potentially upgrading its technical profile to achieve “gold standard” status for CRC at-home testing
Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022
Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer
Executed a $25.8 million (gross) public follow-on offering
Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization
“At the outset of 2022, we established ambitious commercial and product development objectives for the year, mostly around our flagship product ColoAlert. I’m pleased to report that we achieved all of our corporate growth goals for the first half period,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The Company is financially well positioned to maintain momentum as ColoAlert continues to gain impressive commercial traction across Europe and select international territories, and as we ramp up to launch its U.S. pivotal clinical trial by the end of the year.”
$MYNZ
Key Corporate & Product Development Highlights
Accelerated international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC)
Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial Officer
Established partnership with Dante Labs to market ColoAlert in Italy and the United Arab Emirates
Initiated and enrolled the first patient in an international clinical study (ColoFuture) evaluating the integration of novel mRNA biomarkers into ColoAlert – potentially upgrading its technical profile to achieve “gold standard” status for CRC at-home testing
Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022
Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer
Executed a $25.8 million (gross) public follow-on offering
Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization
“At the outset of 2022, we established ambitious commercial and product development objectives for the year, mostly around our flagship product ColoAlert. I’m pleased to report that we achieved all of our corporate growth goals for the first half period,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The Company is financially well positioned to maintain momentum as ColoAlert continues to gain impressive commercial traction across Europe and select international territories, and as we ramp up to launch its U.S. pivotal clinical trial by the end of the year.”
$MYNZ Mainz Biomed Reports First Half 2022 Financial Results
https://finance.yahoo.com/news/mainz-biomed-reports-first-half-070100420.html